Thiazolidinediones tied to lower cancer risk in diabetes patients

Thiazolidinediones tied to lower cancer risk in diabetes patients
(HealthDay) -- Thiazolidinediones are associated with a lower risk of liver and colorectal cancer in patients with type 2 diabetes, according to a study published in the May issue of Hepatology.

Chia-Hsuin Chang, M.D., from the National Taiwan University Hospital in Taipei, and colleagues examined the risk of cancer in 606,583 adult patients with type 2 diabetes without a history of cancer treated with . After a median of 7.9 years, there were 10,741 cases of liver cancer, 7,200 cases of colorectal cancer, 5,361 cases of lung cancer, and 1,583 cases of , with 70,559 controls with diabetes.

The researchers found a significantly lower risk of liver in cancer in patients taking rosiglitazone (odds ratio [OR], 0.73) or pioglitazone (OR, 0.83), with stronger protection for higher cumulative dosages and longer duration. The risk of colorectal cancer was significantly lower only for rosiglitazone (OR, 0.86). There was no association between thiazolidinedione use and lung and bladder cancer, although there was a potentially higher risk of bladder cancer in patients taking pioglitazone for three years or more (OR, 1.56; 95 percent confidence interval, 0.51 to 4.74).

"The use of pioglitazone and rosiglitazone is associated with a decreased incidence in diabetic patients," Chang and colleagues conclude. "The effects on occurrence of specific cancer types may be different for pioglitazone and rosiglitazone."


Explore further

Medical societies respond to the FDA's safety announcement on the use of Actos

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.

Citation: Thiazolidinediones tied to lower cancer risk in diabetes patients (2012, April 27) retrieved 21 May 2019 from https://medicalxpress.com/news/2012-04-thiazolidinediones-tied-cancer-diabetes-patients.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more